MX2019013621A - Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados. - Google Patents

Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.

Info

Publication number
MX2019013621A
MX2019013621A MX2019013621A MX2019013621A MX2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A
Authority
MX
Mexico
Prior art keywords
acting
long
interleuquin
related compositions
receptor agonists
Prior art date
Application number
MX2019013621A
Other languages
English (en)
Inventor
Zhang Ping
Benedict Kirk Peter
Kuo Brewer Peiwen
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2019013621A publication Critical patent/MX2019013621A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación proporciona un agonista del receptor de IL-15 de acción prolongada, composiciones relacionadas y métodos de preparación y uso, por ejemplo, en el tratamiento de afecciones que responden a la terapia efectiva para proporcionar, por ejemplo, actividad inmuno-sostenida y actividad antitumoral.
MX2019013621A 2017-05-15 2018-05-15 Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados. MX2019013621A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762506494P 2017-05-15 2017-05-15
US201762536966P 2017-07-25 2017-07-25
US201762582186P 2017-11-06 2017-11-06
US201862648240P 2018-03-26 2018-03-26
PCT/US2018/032817 WO2018213341A1 (en) 2017-05-15 2018-05-15 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

Publications (1)

Publication Number Publication Date
MX2019013621A true MX2019013621A (es) 2020-01-13

Family

ID=64274790

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019013621A MX2019013621A (es) 2017-05-15 2018-05-15 Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.
MX2024009988A MX2024009988A (es) 2017-05-15 2019-11-14 Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024009988A MX2024009988A (es) 2017-05-15 2019-11-14 Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.

Country Status (10)

Country Link
US (2) US12036283B2 (es)
EP (1) EP3624827A4 (es)
JP (3) JP7316222B2 (es)
KR (2) KR20250057110A (es)
CN (2) CN119700941A (es)
AU (2) AU2018270926C1 (es)
CA (1) CA3060410A1 (es)
IL (2) IL270634B2 (es)
MX (2) MX2019013621A (es)
WO (1) WO2018213341A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020097556A1 (en) * 2018-11-09 2020-05-14 Nektar Therapeutics Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent
EP3946426A4 (en) * 2019-04-05 2023-01-04 Nektar Therapeutics METHOD OF ENHANCING CELLULAR IMMUNOTHERAPY
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
IL288210B2 (en) 2019-05-20 2026-03-01 Cytune Pharma Dosing regimens of IL-2/IL-15 beta-gamma receptor agonists for the treatment of cancer or infectious diseases
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
WO2022090203A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
EP4232068A1 (en) 2020-10-26 2023-08-30 Cytune Pharma IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
CN117597355A (zh) 2021-06-23 2024-02-23 赛腾制药 白细胞介素15变体
KR20240043797A (ko) 2021-08-13 2024-04-03 싸이튠 파마 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합
IL322075A (en) * 2023-02-14 2025-09-01 Akron Bioproducts Llc Pharmaceutical compositions of interleukin for use in vivo
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
AU1096595A (en) 1993-11-12 1995-05-29 Gilead Sciences, Inc. Thrombin mutants
WO1995027722A1 (en) 1994-04-06 1995-10-19 Immunex Corporation Interleukin-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
GEP20084487B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
KR101207247B1 (ko) 2003-01-06 2012-12-03 넥타르 테라퓨틱스 티올-선택성 수용성 중합체 유도체
EP1670501A2 (en) 2003-09-25 2006-06-21 ZymoGenetics, Inc. Methods of treating autoimmune diseases using il-21
TW200613552A (en) 2004-08-11 2006-05-01 Hoffmann La Roche Mutant interleukin-15 polypeptides
JP2008515896A (ja) 2004-10-05 2008-05-15 オクスナー クリニック ファウンデーション Ｉｌ−１５によるｂ細胞増殖の増強
US20060257361A1 (en) 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
HUE025208T2 (en) 2005-06-16 2016-03-29 Nektar Therapeutics Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
EP2134181A4 (en) 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
AU2009209565B2 (en) 2008-02-01 2013-09-19 Ascendis Pharma As Prodrug comprising a self-cleavable linker
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
PL2431741T3 (pl) 2008-10-21 2014-01-31 Baxalta Inc Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro)
TR201908836T4 (tr) 2010-07-30 2019-07-22 Baxalta GmbH Oksim bağına yönelik nükleofilik katalizörler.
WO2012065086A1 (en) * 2010-11-12 2012-05-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
WO2016060996A2 (en) * 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist

Also Published As

Publication number Publication date
IL270634B1 (en) 2025-02-01
JP7316222B2 (ja) 2023-07-27
KR20200003922A (ko) 2020-01-10
JP2020519676A (ja) 2020-07-02
US20200078467A1 (en) 2020-03-12
CN111093688B (zh) 2025-09-16
IL318018A (en) 2025-02-01
EP3624827A1 (en) 2020-03-25
IL270634A (en) 2019-12-31
AU2018270926B2 (en) 2022-04-07
AU2018270926A1 (en) 2019-11-07
CA3060410A1 (en) 2018-11-22
IL270634B2 (en) 2025-06-01
KR102798243B1 (ko) 2025-04-18
US20240424115A1 (en) 2024-12-26
MX2024009988A (es) 2024-08-27
US12036283B2 (en) 2024-07-16
CN111093688A (zh) 2020-05-01
EP3624827A4 (en) 2021-03-03
AU2022203691A1 (en) 2022-06-16
JP7772733B2 (ja) 2025-11-18
JP2025111770A (ja) 2025-07-30
JP2023082218A (ja) 2023-06-13
AU2022203691B2 (en) 2023-10-12
CN119700941A (zh) 2025-03-28
AU2018270926C1 (en) 2022-10-27
KR20250057110A (ko) 2025-04-28
WO2018213341A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
MX2019013621A (es) Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.
AR131056A2 (es) Composiciones para tratar un trastorno hipofosfatémico
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
ECSP17021754A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
ECSP17005276A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
MX389560B (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
AR102712A1 (es) Agonistas parciales del receptor de insulina
MX2016007972A (es) Metodos para tratar canceres con antagonistas de union al eje pd-1 y taxanos.
CL2015002640A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
BR112016023815A2 (pt) composições tópicas para o alívio da dor, produção e uso
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
CL2016000436A1 (es) Método para el tratamiento de la enfermedad fibrótica
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
MX2020004411A (es) Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
MX388845B (es) Uso de pridopidina para tratar el sindrome de rett.
BR112017002354A2 (pt) artigo absorvente extensível
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2017001632A (es) Mioinositol y probioticos, y uso de estos.
UY35823A (es) Profármacos de antagonista de nmda